192 related articles for article (PubMed ID: 24184771)
21. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
Huang J; Zhang F; Jiang L; Hu G; Sun W; Zhang C; Ding X
Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
[TBL] [Abstract][Full Text] [Related]
22. Caveolin-1 sensitizes rat pituitary adenoma GH3 cells to bromocriptine induced apoptosis.
Jiang YN; Li YH; Ke MW; Tseng TY; Tang YB; Huang MC; Cheng WT; Ju YT
Cancer Cell Int; 2007 Mar; 7():1. PubMed ID: 17331262
[TBL] [Abstract][Full Text] [Related]
23. Involvement of p38 mitogen-activated protein kinase activation in bromocriptine-induced apoptosis in rat pituitary GH3 cells.
Kanasaki H; Fukunaga K; Takahashi K; Miyazaki K; Miyamoto E
Biol Reprod; 2000 Jun; 62(6):1486-94. PubMed ID: 10819748
[TBL] [Abstract][Full Text] [Related]
24. Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.
Trouillas J; Chevallier P; Remy C; Rajas F; Cohen R; Calle A; Hooghe-Peters EL; Rousset B
Endocrinology; 1999 Jan; 140(1):13-21. PubMed ID: 9886801
[TBL] [Abstract][Full Text] [Related]
25. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
Ma CY; Lu YC; Shi JX; Ren CC; Zhu JD; Gu JR
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(4):262-6. PubMed ID: 15854489
[TBL] [Abstract][Full Text] [Related]
26. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
27. Either isoform of the dopamine D2 receptor can mediate dopaminergic repression of the rat prolactin promoter.
McChesney R; Sealfon SC; Tsutsumi M; Dong KW; Roberts JL; Bancroft C
Mol Cell Endocrinol; 1991 Aug; 79(1-3):R1-7. PubMed ID: 1834494
[TBL] [Abstract][Full Text] [Related]
28. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
29. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
Wang X; Du Q; Mao Z; Fan X; Hu B; Wang Z; Chen Z; Jiang X; Wang Z; Lei N; Wang H; Zhu Y
Oncotarget; 2017 Jul; 8(28):45874-45887. PubMed ID: 28501857
[TBL] [Abstract][Full Text] [Related]
30. Effects of bromocriptine on cell cycle distribution and cell morphology in cultured rat pituitary adenoma cells.
Johansen PW; Clausen OP; Haug E; Fossum S; Gautvik KM
Acta Endocrinol (Copenh); 1985 Nov; 110(3):319-28. PubMed ID: 4072574
[TBL] [Abstract][Full Text] [Related]
31. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect of bromocriptine on estrogen-induced rat prolactinomas: ultrastructural alterations of secretory granules.
Saitoh Y; Koizumi K; Arita N; Hayakawa T; Mogami H; Matsumoto K; Mori H
Anticancer Res; 1986; 6(5):1149-55. PubMed ID: 3800323
[TBL] [Abstract][Full Text] [Related]
34. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
[TBL] [Abstract][Full Text] [Related]
35. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
36. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen inhibits GH3 cell growth in culture via enhancement of apoptosis.
Lee SY; Ahn BT; Baik SH; Lee BL
Neurosurgery; 1998 Jul; 43(1):116-23. PubMed ID: 9657197
[TBL] [Abstract][Full Text] [Related]
38. Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.
Wu ZB; Zheng WM; Su ZP; Chen Y; Wu JS; Wang CD; Lin C; Zeng YJ; Zhuge QC
J Neurooncol; 2010 Aug; 99(1):25-32. PubMed ID: 20063113
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
40. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.
Kovacs K; Stefaneanu L; Horvath E; Lloyd RV; Lancranjan I; Buchfelder M; Fahlbusch R
Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):439-46. PubMed ID: 2035258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
